1516 related articles for article (PubMed ID: 31957122)
1. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
2. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38281891
[TBL] [Abstract][Full Text] [Related]
4.
Gondoputro W; Doan P; Katelaris A; Scheltema MJ; Geboers B; Agrawal S; Liu Z; Yaxley J; Savdie R; Rasiah K; Frydenberg M; Roberts MJ; Malouf D; Wong D; Shnier R; Delprado W; Emmett L; Stricker PD; Thompson J
Transl Androl Urol; 2023 Oct; 12(10):1598-1606. PubMed ID: 37969779
[TBL] [Abstract][Full Text] [Related]
5. Combined Utility of
Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
[TBL] [Abstract][Full Text] [Related]
6. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
7. The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer.
Bagguley D; Harewood L; McKenzie D; Ptasznik G; Ong S; Chengodu T; Woon D; Sim K; Sheldon J; Lawrentschuk N
BJU Int; 2024 Apr; 133 Suppl 4():27-36. PubMed ID: 37904302
[TBL] [Abstract][Full Text] [Related]
8. The PRIMARY Score: Using Intraprostatic
Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS
J Nucl Med; 2022 Nov; 63(11):1644-1650. PubMed ID: 35301240
[TBL] [Abstract][Full Text] [Related]
9. Detection Rate of
Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
Emmett L; Papa N; Counter W; Calais J; Barbato F; Burger I; Eiber M; Roberts MJ; Agrawal S; Franklin A; Xue A; Rasiah K; John N; Moon D; Frydenberg M; Yaxley J; Stricker P; Wong K; Coughlin G; Gianduzzo T; Kua B; Ho B; Nguyen A; Liu V; Lee J; Hsiao E; Sutherland T; Perry E; Fendler WP; Hope TA
J Nucl Med; 2024 Jan; 65(1):94-99. PubMed ID: 38050155
[TBL] [Abstract][Full Text] [Related]
11. PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer.
Tran V; Hong A; Sutherland T; Taubman K; Lee SF; Lenaghan D; Sethi K; Corcoran NM; Lawrentschuk N; Woo H; Tarlinton L; Bolton D; Spelman T; Thomas L; Booth R; Hegarty J; Perry E; Wong LM
BMJ Open; 2022 Sep; 12(9):e061815. PubMed ID: 36123093
[TBL] [Abstract][Full Text] [Related]
12. Head-to-Head Comparison of
Exterkate L; Hermsen R; Küsters-Vandevelde HVN; Prette JF; Baas DJH; Somford DM; van Basten JA
Eur Urol Oncol; 2023 Dec; 6(6):574-581. PubMed ID: 37230883
[TBL] [Abstract][Full Text] [Related]
13. DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trial.
Krausewitz P; Bundschuh RA; Gaertner FC; Essler M; Attenberger U; Luetkens J; Kristiansen G; Muders M; Ohlmann CH; Hauser S; Ellinger J; Ritter M
Trials; 2023 Mar; 24(1):167. PubMed ID: 36879271
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of
Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of the diagnostic utility of
Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
[TBL] [Abstract][Full Text] [Related]
16. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
17. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
18. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer.
Pepe P; Pepe L; Tamburo M; Marletta G; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2022 Sep; 94(3):274-277. PubMed ID: 36165469
[TBL] [Abstract][Full Text] [Related]
19. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
[TBL] [Abstract][Full Text] [Related]
20. Detection and localisation of primary prostate cancer using
Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
